Search research articles
Contact Us
Filters
Showing results (41-50 of 191) with videos related to
Page
of 20
Sort By:
Urologic Oncology
|
September 22, 2020
Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer
Alicia K Morgans, Neal Shore, Diane Cope, et al.
The Journal of Urology
|
May 2, 2019
Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer
Maxwell V Meng, Jürgen E Gschwend, Neal Shore, et al.
The Canadian Journal of Urology
|
February 18, 2014
Prospective multi-center study elucidating patient experience after prostatic urethral lift
Neal Shore, Sheldon Freedman, Steven Gange, et al.
Urology Practice
|
August 30, 2023
Influencing Best Practices for Genomic and Germline Testing in Urology
Neal Shore, Takara A Scott, Abhishek Srivastava, et al.
Urology
|
November 3, 2024
Evaluating the Importance of Practice-level Factors on Adherence to Prostate Cancer Treatment Guidelines in Urology
Neal Shore, Gordon Brown, Benjamin Lowentritt, et al.
Bladder Cancer (Amsterdam, Netherlands)
|
August 17, 2018
Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E09, Qapzola™) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer
Lawrence Karsh, Neal Shore, Mark Soloway, et al.
Journal of Clinical Anesthesia
|
June 5, 2010
Safety evaluation of fospropofol for sedation during minor surgical procedures
Tong J Gan, Bradley D Berry, Evan F Ekman, et al.
BJUI Compass
|
October 21, 2022
Functional impact of androgen-targeted therapy on patients with castration-resistant prostate cancer
Tomasz M Beer, Neal Shore, Alicia Morgans, et al.
The Journal of Urology
|
April 5, 2021
Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
Susan Halabi, Shan Jiang, Emi Terasawa, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 28, 2024
Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS
Alicia K Morgans, Jamie Partridge Grossman, Noman Paracha, et al.
Page
of 20
Search research articles
Search
Showing results (41-50 of 191) with videos related to
Sort By:
Page
of 20
Urologic Oncology
|
September 22, 2020
Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer
Alicia K Morgans, Neal Shore, Diane Cope, et al.
The Journal of Urology
|
May 2, 2019
Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer
Maxwell V Meng, Jürgen E Gschwend, Neal Shore, et al.
The Canadian Journal of Urology
|
February 18, 2014
Prospective multi-center study elucidating patient experience after prostatic urethral lift
Neal Shore, Sheldon Freedman, Steven Gange, et al.
Urology Practice
|
August 30, 2023
Influencing Best Practices for Genomic and Germline Testing in Urology
Neal Shore, Takara A Scott, Abhishek Srivastava, et al.
Urology
|
November 3, 2024
Evaluating the Importance of Practice-level Factors on Adherence to Prostate Cancer Treatment Guidelines in Urology
Neal Shore, Gordon Brown, Benjamin Lowentritt, et al.
Bladder Cancer (Amsterdam, Netherlands)
|
August 17, 2018
Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E09, Qapzola™) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer
Lawrence Karsh, Neal Shore, Mark Soloway, et al.
Journal of Clinical Anesthesia
|
June 5, 2010
Safety evaluation of fospropofol for sedation during minor surgical procedures
Tong J Gan, Bradley D Berry, Evan F Ekman, et al.
BJUI Compass
|
October 21, 2022
Functional impact of androgen-targeted therapy on patients with castration-resistant prostate cancer
Tomasz M Beer, Neal Shore, Alicia Morgans, et al.
The Journal of Urology
|
April 5, 2021
Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
Susan Halabi, Shan Jiang, Emi Terasawa, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 28, 2024
Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS
Alicia K Morgans, Jamie Partridge Grossman, Noman Paracha, et al.
Page
of 20